Inactive Instrument

Analyst Reco. EntreMed Inc Nasdaq

Equities

US29382F2020

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Mar. 28	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 05	Top Midday Gainers	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Raises Price Target on CASI Pharmaceuticals to $12 From $10, Keeps Buy Rating	Nov. 15	MT
BTIG Adjusts CASI Pharmaceuticals' Price Target to $10 From $21, Keeps Buy Rating	22-11-16	MT
CORRECTION : BTIG Lowers CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept	22-08-15	MT
HC Wainwright Lowers CASI Pharmaceuticals' Price Target to $12 From $30, Buy Rating Maintained	22-08-15	MT
Oppenheimer Adjusts CASI Pharmaceuticals' Price Target to $35 From $6 After Reverse Stock Split, Maintains Outperform Rating	22-08-15	MT
BTIG Raises CASI Pharmaceuticals' Price Target to $21 From $40, Buy Rating Kept	22-06-03	MT
HC Wainwright Adjusts CASI Pharmaceuticals' Price Target to $3 from $4, Keeps Buy Rating	22-05-16	MT
CASI PHARMACEUTICALS : BTIG Initiates CASI Pharmaceuticals at Buy Rating With $4 Price Target	21-05-18	MT
CASI PHARMACEUTICALS : HC Wainwright Adjusts CASI Pharmaceuticals PT to $4 From $3.50, Maintains Buy Rating	21-05-14	MT
CASI PHARMACEUTICALS : Mizuho Security Initiates Coverage on CASI Pharmaceuticals With Buy Rating, $3.80 Price Target	21-04-26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

More Top / Flop

Rankings

More Top / Flop

Currency / Forex

Commodities

Cryptocurrencies

Cryptocurrencies

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer